CompletedPhase 3

Renal MRA Crossover Study Comparing Multihance to Another Contrast Agent

Italy39 participantsStarted 2006-12

Plain-language summary

This is an explorative small pilot study comparing two MRA contrast agents, one of which has been on the market for a few years and the other fairly new to the market. Since the study is explorative and designed to provide preliminary information for consideration for a future larger study, sample size is not based on statistical assumptions.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Known or suspected renovascular disease based on one of the following criteria: * severe hypertension * hypertension refractory to standard therapy * abrupt onset of moderate to severe hypertension at age \< 35 years * normalized blood pressure by an ACE inhibitor in a patient with moderate or severe hypertension * unexplained by stable elevation of serum creatinine \> 2Mg/dL * positive findings for stenosis from another imaging modality

What they're measuring

Sensitivity and specificity compared to DSA

Timeframe: post dose

Trial details

NCT IDNCT00415805

SponsorBracco Diagnostics, Inc

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2008-12

View on ClinicalTrials.gov More Steno-occlusive Disease trials